RT Journal Article
T1 Experiencia del Grupo Español de Trasplante Hematopoyético (GETMON-GETH) en el trasplante alogénico de progenitores hematopoyéticos en leucemia aguda linfoblástica Philadelphia
T2 Experience of the Spanish Group for Hematopoietic Transplantation (GETMON-GETH) in allogenic hematopoietic stem cell transplantation in Philadelphia acute lymphoblastic leukemia
A1 Galan-Gomez, Victor
A1 de-la-Fuente-Regano, Lydia
A1 Rodriguez-Villa, Antonia
A1 Diaz-de-Heredia-Rubio, Cristina
A1 Gonzalez-Vicent, Marta
A1 Badell-Serra, Isabel
A1 Fernandez, Jose Maria
A1 Pascual-Martinez, Antonia Isabel
A1 Perez-Hurtado, Jose Maria
A1 Lopez-Duarte, Monica
A1 Maldonado-Regalado, M. Soledad
A1 Perez-Martinez, Antonio
K1 Acute lymphoblastic leukemia
K1 Philadelphia chromosome
K1 BCR
K1 ABL
K1 Hematopoietic stem cell transplantation
K1 Imatinib
K1 Graft versus host disease
K1 Minimal residual disease
K1 Anti-thymocyte globulin
K1 Versus-host-disease
K1 Open-label
AB Introduction: Outcomes in patients diagnosed of acute lymphoblastic leukemia with Philadelphia chromosome (Ph-ALL) remains unfavourable compared to other subtypes of acute lymphoblastic leukemia despite improvements in drug treatments as well as advances in hematopoietic stem cell transplantation (HSCT). Patients and methods: The role of allogeneic HSCT in Ph-ALL patients has been analysed through a multicentric study where data belonging to 70 patients diagnosed of this entity in different center that received HSCT between years 1998 and 2014, were reported by the Grupo Espanol de Trasplante Hematopoyetico (GETH). Results: The performance of HSCT from year 2004, in first complete remission (CR) status with thymoglobulin (ATG) based conditioning had a favorable impact on overall survival (OS). HSTC performance from year 2004, in first CR with ATG-based conditioning in addition to acute graft versus host disease (aGvHD) development, increased event free survival (EFS). Treatment with imatinib as well as undetectable minimal residual disease (MRD) prior to HSCT, combined with aGvHD, reduced risk of relapse (RR). Patient age less than 10 years when HSCT, first CR and ATG-based conditioning were associated to a lower transplant related mortality (TRM). Conclusions: Patients that could achieve first CR that also received ATG-based conditioning had a better OS and EFS, so HSCT should be considered for this group of patients. (c) 2022 Asociacion Espanola de Pediatria. 
PB Elsevier
SN 1695-4033
YR 2022
FD 2022-03-26
LK https://hdl.handle.net/10668/25726
UL https://hdl.handle.net/10668/25726
LA es
NO Galán Gómez V, de la Fuente Regaño L, Rodríguez Villa A, Díaz de Heredia Rubio C, González Vicent M, Badell Serra I, et al. Experiencia del Grupo Español de Trasplante Hematopoyético (GETMON-GETH) en el trasplante alogénico de progenitores hematopoyéticos en leucemia aguda linfoblástica Philadelphia [Experience of the Spanish Group for Hematopoietic Transplantation (GETMON-GETH) in allogenic hematopoietic stem cell transplantation in Philadelphia acute lymphoblastic leukemia]. An Pediatr (Engl Ed). 2021 Mar 26:S1695-4033(21)00148-X. Spanish
DS RISalud
RD Apr 17, 2025